---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-090064"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2026-08-04T11:20:18+00:00"
generated_at: "2026-08-04T11:25:09.739079+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Theriva Biologics shareholders approve 2M share increase in stock plan, reelect directors at 2026 annual meeting

## Summary
- Shareholders approved Amendment No. 4 to 2020 Stock Incentive Plan, increasing shares from 4.5M to 6.5M.
- All four director nominees elected: Kraws, Shallcross, Monahan, Wolf.
- Ratified BDO USA as independent auditor for FY2026.
- Approved charter amendment to increase authorized shares; Board has discretion to file.
- Approved issuance of common stock upon exercise of outstanding warrants.

## SEC filing metadata
- accession: 0001104659-26-090064
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2026-08-04T11:20:18+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465926090064/0001104659-26-090064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465926090064/tm2619846d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-090064
- JSON: https://secwatch.observer/filing/0001104659-26-090064.json
- Plain text: https://secwatch.observer/filing/0001104659-26-090064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.